Magnesium, zinc, arsenic, selenium and platinum urinary excretion from cancer patients of Antofagasta region, Chile: multi-metal approach

DA Román, I Pizarro, L Rivera, J Ávila and P Cortés
Department of Chemistry, Faculty of Basic Science, Bioinorganic and Environmental Analytical Chemistry Laboratory, University of Antofagasta, Antofagasta 124000, Chile
Corresponding author: DA Román. Email: domingo.roman@uantof.cl

Summary
Objectives: To evaluate the short-term 24 h urinary excretion of platinum, arsenic, selenium, magnesium and zinc in patients with lung cancer and with cancer other than lungs treated with cisplatin or/and carboplatin from Antofagasta, Chile.
Design: Urine measurements of Pt and Se were made by inductively coupled plasma optical emission spectrometry, As by hydride-generation atomic absorption spectrometry and Mg and Zn by means of flame furnace atomic absorption spectrometry.
Setting: All samples were provided by the Oncological Centre of Antofagasta Regional Hospital (Region of Antofagasta, Chile).
Participants: Ninety 24-h urine samples from cancer patients after the infusion of Pt-base drugs and 10 24-h urine samples from cancer patients not treated with metal-base drugs.
Main outcome measures: Concentrations of Pt, Se, As, Zn and Mg coming from 24-h urine samples.
Results: Pt excreted was not significantly different between patients with lung and other cancers treated with cisplatin. The excretion of Mg, Zn and Se was greater than As. Then, Pt favours the excretion of essential elements. For lung and other types of cancers treated with drugs without Pt, excretion of Mg, Zn and Se was also greater than that of As, suggesting antagonism Mg-Zn-Se–anti-cancer drug relationship.
Conclusions: The amounts of Mg, Zn and Se excreted were greater than for As either with or without Pt-containing drugs, suggesting antagonist Mg-Zn-Se–anti-cancer drug relationships. The excretion of As, Mg, Zn and Se is induced by Pt. Knowledge obtained can contribute to understanding the arsenic cancer mechanism and the As-Mg-Zn-Se-Pt inter-element association for lung cancer and other types of cancer.

Keywords
Cancer, platinum-based drugs chemotherapy, heavy metal short-term urinary excretion, magnesium, arsenic, zinc, selenium platinum, urine, inter-element relationships

Introduction
The deterioration in the environmental health of people living in Antofagasta, Chile could be associated with medical geology characteristics of this part of the Atacama Desert ecosystem and the extensive mining related activities carried out in this geographical zone that exposes the inhabitants to an increasing risk of cancer, cardiovascular diseases and neurological diseases. Geological structures in certain places on Earth influence human health1,2 and the underlying cause could be the multi-metallic synergy of heavy metals.3 Arsenic (As) is one of the main environmental stressors that affects the quality-of-life of the population 4–7 in the Antofagasta region in Chile; Antofagasta is a highland–coastal desert ecosystem in which large-scale mining activities have been conducted for a long time.8 These activities have affected the ecosystems and the quality-of-life of the people living there.9

Cancerous and non-cancerous diseases associated with As contamination are known in several parts of the world.10 However, this association reaches alarming levels in the Antofagasta region, as evidenced by the incidence of cardiovascular diseases3 and cancer.4,7,11 The mortality rates due to cancer in the Antofagasta region are higher than those in any other population exposed to As in the world.12 Most therapeutic treatments are based on the action of platinum group metals under the form of metal-based drugs.13–15

There is a large body of evidence about the trace element ecosystem impact and the cancer development.3 The toxic effect of metals are involved in a variety of diseases, some related to heavy metal stress and others to the imbalance of essential metals due to human multi-elemental exposure.3 So, both approaches need multi-element hypothesis.
The precious heavy metal Pt is of considerable interest because of its emission from automotive catalysts, its use in prostheses and in Pt-based anti-tumour drugs. Administration of Pt-based drugs has an impact at the cellular level, affecting metabolism, homeostasis and physiology in humans. The main side effects of the application of Pt drugs are loss of hearing (ototoxicity), kidney dysfunction (nephrotoxicity) and resistance to anti-cancer drugs. As in other anti-cancer drugs, the principal disadvantage of these treatments is the metastasis.

Despite of the advances in cancer treatments, the cytotoxicity of chemotherapies continues to be an important problem. Problems arising from erroneous calculation of the Pt-based dose drugs when the body surface area (BSA) method is applied, which can influence the Pt inter-element interactions with elements such as Mg, Zn, As and Se and the corresponding metal-creatinine ratios values. Nevertheless, failure in correctly applying the BSA method does not account for the marked inter-patient variation in drug handling. Therefore, drug effects such as toxicity or consequences due to unexpected under-dosing are unpredictable.

Most toxicology studies focus on a single agent, but this approach does not reflect real-world scenarios in which humans are exposed here and now to multiple chemicals. The toxicity of an element may be reinforced or weakened through its inter-element interactions. Such interactions are, in general, classified as being ‘adversely additive’, ‘synergistic (greater than additive)’ or ‘antagonistic’ (less than additive or even acting as antidotes to one another). Antagonistic behaviour between As-Se and Pt-Se pairs has been observed in humans. Hence, the level of Se in urine could be particularly of interest when assessing exposure to heavy metals. Inasmuch cisplatin and carboplatin caused suppression of anti-oxidant enzyme protection via mitochondrial dysfunction. Selenium would strengthen the capacity of antioxidant-protecting components of cells (e.g., nucleic acids) from damage of reactive oxygen species through antioxidant Se-based and Zn-based enzymes such as glutathione peroxidase and thioredoxin reductase, which require Se(IV) for their expression and Zn-superoxide dismutases. Several hypotheses have been stated to account for experimental data, which indicates that Se compounds have anti-cancer properties. However, although evidence has been accumulating in support of the ‘Se chemo protective hypothesis’, definitive proof is lacking. Otherwise, the vulnerability of the antioxidant-protecting components of cells can also result in side effects, such as metastasis and resistance to Pt-based drugs.

Evidence suggests that As inhibits the potential anti-cancer effects of Se, and also its interaction with essential trace elements and other heavy metals such as copper, zinc, cadmium, mercury, tin, lead, nickel, cobalt, antimony, silver, gold and molybdenum. A study on the urinary excretion of Se and As in pregnant women from northern Chile found a significant association between the urine concentrations of these elements. Drugs that contain Pt (e.g. cisplatin and carboplatin) have been shown to increase the biliary excretion and distribution of Se in tissues, but Pt has not been shown to significantly influence the urinary or respiratory excretion of Se. The distribution of Se in tissues is altered by cisplatin, which results in high concentrations of Se in the liver, kidney and plasma, and low levels of Se in the testicles and brain. The underlying mechanism of Se homeostasis is incompletely understood.

Most toxicology studies focus on a single agent, but this approach does not reflect real-world scenarios in which humans are exposed here and now to multiple chemicals. The toxicity of an element may be reinforced or weakened through its inter-element interactions. Such interactions are, in general, classified as being ‘adversely additive’, ‘synergistic (greater than additive)’ or ‘antagonistic’ (less than additive or even acting as antidotes to one another). Antagonistic behaviour between As-Se and Pt-Se pairs has been observed in humans. Hence, the level of Se in urine could be particularly of interest when assessing exposure to heavy metals. Inasmuch cisplatin and carboplatin caused suppression of anti-oxidant enzyme protection via mitochondrial dysfunction. Selenium would strengthen the capacity of antioxidant-protecting components of cells (e.g., nucleic acids) from damage of reactive oxygen species through antioxidant Se-based and Zn-based enzymes such as glutathione peroxidase and thioredoxin reductase, which require Se(IV) for their expression and Zn-superoxide dismutases. Several hypotheses have been stated to account for experimental data, which indicates that Se compounds have anti-cancer properties. However, although evidence has been accumulating in support of the ‘Se chemo protective hypothesis’, definitive proof is lacking. Otherwise, the vulnerability of the antioxidant-protecting components of cells can also result in side effects, such as metastasis and resistance to Pt-based drugs.

Evidence suggests that As inhibits the potential anti-cancer effects of Se, and also its interaction with essential trace elements and other heavy metals such as copper, zinc, cadmium, mercury, tin, lead, nickel, cobalt, antimony, silver, gold and molybdenum. A study on the urinary excretion of Se and As in pregnant women from northern Chile found a significant association between the urine concentrations of these elements. Drugs that contain Pt (e.g. cisplatin and carboplatin) have been shown to increase the biliary excretion and distribution of Se in tissues, but Pt has not been shown to significantly influence the urinary or respiratory excretion of Se. The distribution of Se in tissues is altered by cisplatin, which results in high concentrations of Se in the liver, kidney and plasma, and low levels of Se in the testicles and brain. The underlying mechanism of Se homeostasis is incompletely understood.

Studies looking at urinary excretion of Pt among patients treated with cisplatin have been conducted on average between 6 months and 16.8 years after treatment. In the present work, we investigated the excretion of Mg, Zn, As, Se and Pt in 24-h urine samples after the infusion of Pt based-drugs to cancer patients. Short-term monitoring of urine after the first cycles of treatment with Pt-based drugs could be a good approach for studying the inter-element interaction among Mg, Zn, As, Se and Pt in patients whose cancer was probably triggered by As exposure. Such knowledge could contribute to better understanding of the mechanisms of side effects and resistance to Pt-based drugs, improving the calculation of optimal doses of anti-cancer drugs and understanding the resistance (or permissiveness) to metastasis.

In this work, we study the amounts of magnesium, zinc, arsenic, selenium and platinum in five groups of urine samples of patients with cancer coming from the Region of Antofagasta – Chile. Information was obtained about the inter-element relationships Mg–Zn, Zn–Se, Zn–As, As–Se, Zn–Pt and As–Pt pairs in short-term 24-h urine excretion of persons with cancer from Antofagasta – Chile; platinum has been supplied as cisplatin and/or carboplatin.

**Materials and methods**

The work was carried out in accordance with the Health Service of Antofagasta (Antofagasta, Chile) according to ORD 4391; the study protocol was also authorised by the Ethics and Biosafety Committee of Antofagasta University.
Study population and collection of samples

Ten 24-h urine samples from cancer patients of the Antofagasta region were collected before Pt-based drugs chemotherapy was initiated. Ninety 24-h urine samples from cancer patients were collected immediately after the infusion of the Pt-based drugs; and 10 24-h urine samples were collected from patients subjected to chemotherapy not involving metal-based drugs. All samples were provided by the Oncological Centre of Antofagasta Regional Hospital (Region II, Chile). The 90 cancer patients are distributed in the following cases: 32 lung cancer, 16 ovarian cancer, 12 cervical-uterine cancer, 8 testicular cancer, 5 thymus cancer, 3 oesophageal cancer, 3 gastric cancer, 3 Hodgkin lymphomas, 2 vagina cancer, 2 bladder cancer and one each of gall-bladder, tonsil, salivary gland and osteosarcoma cancers. The dose calculation for chemotherapy had been made by the BSA method. Three of the four patients with ovarian cancer initially treated with cisplatin were again treated with cisplatin after 28 days, whereas the fourth patient was treated with carboplatin. Cancer affecting other parts of the human body than lungs was categorised as 'other cancers'; only patients in this group were treated with carboplatin. Samples were collected between May and August 2005.

Chemicals, solutions, materials and instruments

The chemicals employed were Instra (J.T. Baker, Phillipsburg, NJ, USA) and Suprapur (Merck, Whitehouse Station, NJ, USA), both of which were of trace-element grade. Solutions were prepared in deionised water that was subsequently distilled in quartz (conductivity, <0.5 μMHO/cm at 25°C). The deionisation was undertaken in a deioniser with two ion-exchange cartridges – a Metex 01506-45 and a Research 01506-35 (Cole-Parmer, Waltham, MA, USA) – connected in tandem.

The glass materials used were sequentially treated for 24 h with 2-M solutions of hydrochloric acid and nitric acid prepared from Merck pro analysis quality grade chemicals. After being washed with water, the glass materials were treated for another 24 h with a 0.025 M disodium salt of ethylenediamine tetraacetic acid solution prepared from Titriplex III (Merck), after which they were rinsed with water.

Pt(II) standard dilutions were prepared from a primary solution of Certipur (Merck) and those of Mg, Zn and Se(IV) were prepared from Titrisol (Merck) primary solutions; the concentration of primary solutions was 1000 mg L–1. An intermediate 50 mg L–1 standard solution was made, which was used to prepare the working dilutions. Standard As solutions were prepared from a 1000 mg L–1 primary solution of disodium arsenate Titrisol (Merck), from which a 500 mg L–1 intermediate standard dissolution was prepared for the working dilutions. To generate arsenic hydride, 10 M chlorhydric acid solution was used, which was prepared from Instra (J.T. Baker). A 3% p/v sodium borohydride solution was prepared in a 1% p/v sodium hydroxide solution, both of which were Merck pro analysis grade quality chemicals.

Urine samples digestion

Urine samples and controls were mineralised using the wet method in Teflon bombs with 10 mL of nitric acid (Instra; J.T. Baker, USA) for 2 h at 150°C in a homemade ceramic oven with an internal temperature sensor and external temperature control. After the samples were cooled, the oven was opened and an additional 0.25 mL of perchloric acid and 0.50 mL of sulphuric acid were added to the Teflon bombs with the digested samples; both acids were of Suprapur grade (Merck). Samples were then reheated under the same conditions of time and temperature as described above. Finally, samples were transferred to Erlenmeyer flasks and heated at 300°C under a gas extraction hood to eliminate excess acids. Sample volumes were made up to 50 mL with deionised water, and then micro-filtered through a 0.22-μm Millipore membrane with a 0.7-μm fiberglass pre-filter (Advantec-MFS, Japan).

To determine total As concentrations, 5-mL aliquots of samples and controls were digested
to semi-reflux under a temperature programme between 85°C and 300°C. After cooling, samples and controls were diluted volumetrically with 0.5 M HCl prepared from Instra quality grade chemical (J.T. Baker, USA).

### Determination of total Pt and Se in urine through inductively coupled plasma optical emission spectrometry

With the aim of meeting the matrix-matching conditions, aliquots of three samples of digested urine were titrated with NaOH secondary standard solution, yielding an average acidity equivalent to a pH of 2. To make compatible the matrix-matching conditions of the analytical blanks, seawater was diluted 8-fold, 10 mL of sample was diluted to a final volume of 50 mL and, when necessary, the solution was adjusted to pH 2 with Instra nitric acid (J.T. Baker, USA). The bimetallic Pt–Se standard was also subsequently prepared in this medium.

Inductively coupled plasma optical emission spectrometry (ICP-OES) calibration curves were constructed from a 50 μg/mL Pt–Se bimetallic standard at the following Pt/Se concentrations: 100/100; 500/200; 1000/300; 2500/400; and 5000/500 ng/mL. The bimetallic standard with the highest concentration was used to optimise the instrumental parameters. ICP-OES measurements were done on a GBC Integra XL Spectrometer (Integra, Canberra, Australia) equipped with a spray trace nebuliser chamber and a 200 μL Micromist nebuliser (Glass Expansion, Melbourne, Australia). Analytical-grade 5 N₂ and Ar gases were used. The optimised experimental conditions are shown in Table 1. The baseline was adjusted with the analytical blank solution, and quality-control (QC) tests were made by evaluating the recovery of Pt–Se internal standard additions over blank and real samples. Before the patient urine measurements were made, the samples underwent the abovementioned procedures and analytical methods.

### Determination of total As, Mg and Zn concentrations in urine by hydride-generation atomic absorption spectrometry and flame furnace atomic absorption spectrometry

Determination of As was undertaken using an atomic absorption spectrophotometer (GBC 909 AA; GBC Victoria, Australia) equipped with a continuous-flow hydride generator (GBC HG 3000) and an electro-thermal atomization system (GBC EHG 3000).

| As HG-AAS                  | Bandpass width | 2 nm  |
|----------------------------|----------------|-------|
|                            | Bandpass height | Normal|
|                            | Lamp current   | 8.0 mA|
|                            | Boost current  | 30 mA |
|                            | Temperature    | 920°C |
|                            | N₂ flow        | 45–50 mL/min |
|                            | Time signal stabilization | 60 s |
|                            | Reading time   | 10 s  |
| Pt–Se ICP-OES              | Spectral line of Pt | 265.945 nm |
|                            | Spectral line of Se | 196.026 nm |
|                            | Nebulising flow | 0.40 L/min |
|                            | Line detection height | 6.8 mm |
|                            | Pump           | 17.0 r/min |
|                            | Power          | 1200 W  |
|                            | Auxiliary gas  | 0.6 L/min |
|                            | Ar feed        | 12.0 L/min |
|                            | Nebulising chamber | Spray trace; 200 μL Micromist nebuliser |
| Mg – Zn FFAAS              | Bandpass width (nm) | 0.5 |
|                            | Bandpass height | Normal |
|                            | Lamp current (mA) | 4 |
|                            | Boost current (mA) | 5 |
|                            | Flame temperature (°C) | 1200 |
|                            | Time signal stabilization (s) | 60 |
|                            | Reading time (s) | 3 |

HGAAS: hydride-generation atomic absorption spectrometry; ICP-OES: inductively coupled plasma optical emission spectrometry; FAAS: furnace atomic absorption spectrometry
GBC quartz cells and an As-boosted current lamp from Photon (Narre Warren, Victoria, Australia) were also used. The optimised conditions for measuring As through hydride-generation atomic absorption spectrometry (HGAAS) are presented in Table 1. Multiple-standard-addition methodology was also applied and the additions were made from an intermediate 500 mg/L standard solution prepared in 0.5 M HCl from a primary standard arsenic solution (Titrisol, Merck). Additions from this solution were made to surrogate-sample urine, which had been made up to 2.0 μg/L in As. The addition volumes were 50, 100, 150 and 200 μL; the concentrations added were therefore 2, 4, 6 and 8 ng/mL, respectively.

For Mg and Zn, urine analysis FFAAS was applied in the GBC 909 AA atomic absorption spectrometer employing a GBC quartz atom trap cell (Australia) and Photon hollow cathode lamps (Australia). The optimised conditions for Mg and Zn analysis are presented in Table 1. For Mg, a standard dilution of 100 mg/L in 0.3 M HCl was prepared from the Titrisol standard solution (Merck). From this solution, the standard measurement dilutions were prepared using seawater as ‘surrogate urine’. The analytical concentrations for the calibration curve standard dilutions were 5.0, 10.0, 15.0, 20.0 and 25.0 mg/L. For Zn, the multiple standard additions methodology was also applied. In this case, the additions were also made over the ‘surrogate urine’ from one zinc standard dilution of 100 mg/L prepared in 0.3 M HCl from the corresponding Zn Titrisol standard solution (Merck). Surrogate urine was made 400 μg/L in Zn and the additions were of 100, 200, 300 and 400 μL. So, the added concentrations were of 400, 800, 1200 and 1600 ng/mL, respectively.

The baseline was adjusted with the analytical blank solution, i.e. diluted surrogate urine. QC tests were conducted to evaluate the recovery of Mg, Zn and As from Mg-, Zn- and As-spiked real samples, measurement of secondary standards were also made. Urine samples of patients underwent the abovementioned procedures and analytical methods.

Urine and serum creatinine levels and calculation of creatinine clearance

Levels of urine and serum creatinine were measured using the Jaffé method. Creatinine clearance rate (CrCl) was calculated using the Cockcroft–Gault equation. Serum creatinine is the blood clearance or endogenous blood creatinine depuration, and their values were provided by the Oncological Center of Antofagasta Regional Hospital. Urine and serum CrCl values are used to evaluate renal dysfunction. The estimated CrCl for normal renal function should be >80 mL/min.

Statistical analyses

Statistical analyses were conducted using the Statistica 10.0 MR1 software (StatSoft, Tulsa, OK, USA). p < 0.05 was considered significant.

Results and discussions

Determination of Mg, Zn, Pt, As and Se

The ICP-OES calibration curves for total Pt and Se concentrations in urine were linear. In the case of Pt, the parameters of the calibration equation were intercept = 93.45 counts s⁻¹, slope = 1.079 counts s⁻¹/concentration and r = 0.9998. For Se, the parameters were intercept = 55.47 counts s⁻¹, slope = 1.720 counts s⁻¹/concentration and r = 0.9880.

The resulting standard-addition methodology parameters for As urinary analysis were also analytically suitable: intercept = 0.0375 μA, slope = 0.01615 μA/concentration and r = 0.9977.

The FFAAS urine calibration was also linear and the equation parameters were: intercept = −0.1243 μA, slope = 0.0523 μA/concentration and r = 0.9948. The multiple standard addition methodology parameters for Zn measurements were intercept 0.0051 μA, slope = 0.000495 μA/concentration and r = 0.9988. All analytical techniques were validated by means of the inner standard addition methodology. The results of the QC test and analytical validation are presented in Table 2.

The analytical validation and QC results for Pt and Se by ICP-OES, As by HGAAS, Mg and Zn by FFAAS analyses in 24-h urine samples of cancer patients indicated that the techniques and methodologies applied in this work were analytically suitable. Surrogate urine prepared with clean seawater was important for optimisation of the analytical parameters and appropriate representativeness of the results.

Inter-element relationship of Mg, Zn, Pt, As and Se in urine of cancer patients from the Antofagasta Region of Chile treated with Pt-based drugs

Knowledge in this area is mainly based upon single elements; a better-known case is that of As, which has been associated with several diseases, including cancer. However, recent developments in multielemental analytical techniques and methodologies have enabled exploration of inter-elemental
relationships and toxicities of essential elements and heavy metals, which coexist in environmental and biological matrices.\textsuperscript{58–63} However, it has become increasingly clear that simple, single-element models are often inadequate to explain the relationship between disease and nutrition, element toxicity or deficiency of elements in food. Improved understanding of the synergistic and/or antagonistic interactions between trace elements is needed.\textsuperscript{64} A multi-elemental hypothesis may be a better approach to understanding these relationships.

Renal function before and after cancer treatment with Pt-based drugs is an important parameter. Before starting anti-cancer treatment, it is advisable that the CrCl is >60 mL/min.\textsuperscript{52,65} Patients with lower values have an increased risk of severe suppression of the bone marrow. The CrCl for normal renal function is > 80 mL/min.\textsuperscript{52,66} The CrCl values before Pt-based drug chemotherapy for the control group 2 (baseline patients; see below) were 93.3–114.6 mL/min; serum and urine creatinine values were 0.6 – 0.9 and 0.8–1.1 mg/dL, respectively. Evidently, Pt-based drug chemotherapy impacts the CrCl and the metal/creatinine quotient values; both parameters are considered controversial.\textsuperscript{67,68} According to this approach, after chemotherapy, 82 of 90 cancer patients had kidney damage.

**Statistical parametric treatment**

Tables 3 and 4 show the main parametric statistic results found in 24-h urine samples of five cancer patient groups under study from Region II (Antofagasta). That is (1) lung cancer treated with cisplatin, (2) cancer other than lung cancer treated with cisplatin, (3) cancer other than lung cancer treated with carboplatin, (4) cancer other than lung treated with drugs not containing metals (control 1) and (5) lung and other than lung cancer before the chemotherapy began, which can be considered as the baseline group (control 2). The number of patients in group 3 and in each one of the control groups was fewer than 11 cancer cases, respectively. Normal distribution of the data was proven by applying the Shapiro–Wilk normality test. For groups 1–2 with more than 11 cancer patient cases, the Shapiro–Wilk normality test was also applied. One-way ANOVA ($p \leq 0.05$) test was applied to determine the level of significance of the data. If the data of groups 1 and 2 followed a normal or a non-normal distribution, the most representative group value considered was the mean or the median, respectively. In Tables 3 and 4, the number of As and Se results are less than the total number of cancer types (n) because in some urine samples the amount of elements were below the detection limit of the applied analytical technique.

Although the number of patient with cancer of the control groups was low, we can observe that in both cases the Se levels tend to be higher than those of As. However, in control group 2, the range of As and Se levels tends to be comparable or slightly smaller than those of control group 1. In Antofagasta Region, the Se concentrations have been shown to be higher than those As in the umbilical cords and placentas of normal and malformed newborn born babies, as well as in the tissues of patients and tissues of patients subjected to cardiovascular surgeries.\textsuperscript{69,70} This characteristic was also observed in the present study, inasmuch that the Se and As concentrations in group 3 were comparable with those of control 1 and control 2 groups.

**Multivariate statistical treatment**

The cluster technique was applied to the involved variables (i.e. calculated amounts of Pt supplied through Pt-based drugs and the urinary amounts of Mg, Zn, Pt, As and Se excreted in 24-h urine after the cancer patients’ chemotherapy with cisplatin). Cluster analysis is a multivariate statistical methodology applied to datasets if there is a lack of information

---

**Table 2. Traceability and quality control of urinary analyses of Mg, Zn, As, Se and Pt in cancer patients.**

| Analyte | N | Added (ng/mL) | Found (ng/mL) | Yield (%) | ± RSD (%) | RE (%) | DL (ng/mL) |
|---------|---|---------------|---------------|-----------|----------|--------|-----------|
| Pt      | 11| 1000          | 971.0         | 97.1      | 5.7      | 2.9    | 7.7       |
| Se      | 11| 300           | 290.9         | 97.0      | 6.3      | 3.0    | 5.4       |
| As      | 11| 4             | 3.87          | 96.7      | 6.1      | 3.3    | 0.22      |
| Mg      | 11| 15000.0       | 14400.0       | 96.0      | 6.3      | 4.0    | 3.2       |
| Zn      | 11| 400.0         | 388.0         | 97.0      | 5.7      | 3.0    | 3.0       |

RSD: relative standard deviation; RE: relative error; DL: detection limit.
Table 3. Basic statistical values for the group patients treated with Pt-based drugs and control group treated without Pt-based drug and the baseline group. Amounts of supplied Pt and Pt, Mg, Zn, As and Se in 24-h urine samples.

| Groups               | Type of cancer | Parameter | Pt Supp (mg) | Pt (μg) | Se (μg) | As (ng) | Mg (mg) | Zn (μg) |
|----------------------|----------------|-----------|--------------|---------|---------|---------|---------|---------|
| Cisplatin (Group 1)  | Lung           | X         | 163.0        | 35.3    | 3.62    | 127.0   | 0.45    | 17.93   |
|                      |                | Med       | 156.0        | 28.2    | 1.28    | 23.5    | 0.11    | 15.85   |
|                      |                | DS        | 66.6         | 25.9    | 6.45    | 267.0   | 0.71    | 10.29   |
|                      |                | n         | 32           | 32      | 24      | 21      | 32      | 32      |
|                      |                | Min       | 39.1         | 3.94    | 0.208   | 1.88    | 0.10    | 9.58    |
|                      |                | Max       | 263.0        | 90.4    | 22.0    | 1180.0  | 2.64    | 65.89   |
| Cisplatin (Group 2)  | Other          | X         | 174.0        | 40.1    | 1.35    | 216.0   | 0.37    | 14.10   |
|                      |                | Med       | 120.0        | 32.5    | 1.22    | 71.0    | 0.20    | 12.68   |
|                      |                | DS        | 324.0        | 36.1    | 0.717   | 424.0   | 0.57    | 4.56    |
|                      |                | n         | 47           | 47      | 36      | 31      | 47      |         |
|                      |                | Min       | 31.6         | 0.760   | 0.354   | 18.8    | 0.10    | 5.63    |
|                      |                | Max       | 2297.0       | 175.0   | 2.84    | 2300.0  | 2.65    | 25.17   |
| Carboplatin (Group 3)| Other          | X         | 695.0        | 262.0   | 1.59    | 40.8    | 0.77    | 15.10   |
|                      |                | Med       | a            | a       | a       | a       | a       |         |
|                      |                | DS        | 189.0        | 201.0   | 0.711   | 46.9    | 0.90    | 3.49    |
|                      |                | n         | 11           | 11      | 9       | 6       | 9       |         |
|                      |                | Min       | 433.0        | 9.80    | 0.516   | 2.53    | 0.10    | 11.25   |
|                      |                | Max       | 917.0        | 680.0   | 2.52    | 121.0   | 2.0     | 20.89   |
| Control 1 (b) (Group 4)| Other       | X         | 1.77         | 62.0    | 1.11    | 14.13   |         |         |
|                      |                | Med       | a            | a       | a       | a       |         |         |
|                      |                | DS        | 1.14         | 59.4    | 1.16    | 6.44    |         |         |
|                      |                | n         | 7            | 2       | 10      | 10      |         |         |
|                      |                | Min       | 0.333        | 20.0    | 0.10    | 1.20    |         |         |
|                      |                | Max       | 3.29         | 104.0   | 3.0     | 23.58   |         |         |
| Control 2 (c) (Group 5)| Lung and other| X         | 1.47         | 48.2    | 0.11    | 9.76    |         |         |
|                      |                | Med       | a            | a       | a       | a       |         |         |
|                      |                | DS        | 0.58         | 1.56    | 0.070   | 4.23    |         |         |
|                      |                | n         | 9            | 2       | 10      | 10      |         |         |
|                      |                | Min       | 0.45         | 47.1    | 0.05    | 5.27    |         |         |
|                      |                | Max       | 2.16         | 49.3    | 0.27    | 15.62   |         |         |

Supp: supplied; X: mean; Med: median; SD: standard deviation; n: number of cases; Min: minimum value; Max: maximum value. (a) Due to the small number of cases, the median values were not reported; (b) non-platinum drugs treatment; (c) patients without chemotherapy (two gastric cancer, two bladder cancer and five lung cancer).
Table 4. Basic statistical values for the group patients treated with Pt-based drugs and control group treated without Pt-based drug and the baseline group. Pt, Mg, Zn, As and Se amounts in 24-h urine samples expressed as metal (g creatinine)⁻¹.

| Groups                  | Type of cancer | Parameter | µg Pt/g Cr | µg Se/g Cr | mg As/g Cr | mg Mg/gCr | mg Zn/gCr |
|-------------------------|----------------|-----------|------------|------------|------------|------------|------------|
| Cisplatin (Group 1)     | Lung           | X         | 1.05       | 143.0      | 5.57       | 48.94      | 19.10      |
|                         | Med            |           | 1.06       | 49.0       | 2.08       | 35.45      | 13.26      |
|                         | DS             | 0.625     | 263.0      | 8.94       | 77.71      | 12.10      |
|                         | n              | 32        | 24         | 21         | 33.0       | 33         |
|                         | Min            | 0.136     | 7.0        | 0.360      | 10.74      | 9.68       |
|                         | Max            | 2.52      | 1028.0     | 31.1       | 294.97     | 65.89      |
| Cisplatin (Group 2)     | Other          | X         | 1.39       | 83.9       | 7.96       | 21.45      | 14.03      |
|                         | Med            |           | 0.969      | 40.7       | 2.55       | 15.78      | 10.50      |
|                         | DS             | 1.59      | 186.0      | 17.1       | 36.2       | 4.57       |
|                         | n              | 47        | 36         | 31         | 47         | 47         |
|                         | Min            | 0.110     | 11.3       | 0.280      | 1.85       | 5.63       |
|                         | Max            | 7.26      | 1136.0     | 91.2       | 231.28     | 27.80      |
| Carboplatin (Group 3)   | Other          | X         | 13.3       | 156.0      | 10.1       | 1047.40    | 15.10      |
|                         | Med            |           | a          | a          | a          | a          |
|                         | DS             | 9.76      | 182.0      | 18.5       | 2845.8     | 3.49       |
|                         | n              | 11        | 9          | 6          | 9          | 9          |
|                         | Min            | 0.780     | 25.5       | 0.40       | 5.49       | 11.25      |
|                         | Max            | 32.5      | 484.0      | 47.7       | 9095.23    | 20.89      |
| Control 1 (b) (Group 4) | Other          | X         | 51.6       |           | 36.50      | 14.10      |
|                         | Med            |           | a          | a          | a          |
|                         | DS             | 33.7      |           | 51.9       | 6.40       |
|                         | n              | 7         | 10         | 10         | 10         |
|                         | Min            | 5.30      | 2.23       | 1.20       |
|                         | Max            | 92.3      | 145.96     | 23.58      |
| Control 2 (c) (Group 5) | Lung and other | X         | 61.9       | 3.60       | 0.34       |
|                         | Med            |           | a          | a          |
|                         | DS             | 20.4      | 1.89       | 0.17       |
|                         | n              | 9         | 10         | 10         |
|                         | Min            | 28.1      | 1.87       | 0.26       |
|                         | Max            | 90.4      | 8.10       | 0.82       |

Supp: supplied; X: mean; Med: median; SD: standard deviation; n: number of cases; Min: minimum value; Max: maximum value. (a) Due to the small number of cases, the median values were not reported; (b) non-platinum drugs treatment; (c) patients without chemotherapy (two gastric cancer; two bladder cancer and five lung cancer).
about the classes comprising the data. The basic objective is to group the variables by similarities. The basic objective is to group the variables by similarities. The technique is based on two aspects: the way the distance between the variables is measured (metric) and the groupings or clusters (linkage or amalgamation rule). The technique was applied to the most representative sets of values in accordance with the Shapiro–Wilk normality test. Ward’s method was applied with Pearson’s r approximation to measure the distance between variables and the groupings or clusters.

Figure 1 shows the dendrogram of metal amounts in 24-h urine after the cisplatin first cycle treatment to lung-cancer patients, and Figure 2 shows the two main variables grouping, that is to say, (Pt exc, Se exc) and (Mg exc, Zn exc, As exc) when the principal component multivariate technique was applied, that is to say (Pt exc and Se exc) and (Mg exc, Zn exc and As exc). Then, Pt sum coming from cisplatin is not a principal component for lung cancer patients under orthog- onal conditions. Therefore, this result would confirm that platinum from cisplatin is predominantly distributed and bio-accumulated in the cancerous and healthy tissues under less active anti-cancer platinum forms.

The effect of Pt sum is critical over As exc, Se exc, Zn exc and Mg exc. So, besides Pt and As, two heavy metals, Se was considered as a critical essential and anti-cancer element, and Mg and Zn two acknowledged essential elements were also considered in this work. Consequently, the information obtained in this work about urinary levels of this set of elements with less active d orbital electrons immediately after cancer patients were subjected to chemotherapy with Pt-based drugs could contribute to a better understanding of the adverse effects of Pt and help in the more accurate estimation of drug doses. Consideration of urinary levels of carcinogens such as As and cancer-fighting nutrients such as Mg, Zn and Se could allow more individualised or dedicated strategies for predictive calculations of drug dosages to be applied to cancer patients.

A well-established correlation has been found between As exposure in the Antofagasta region of Chile and the risk of cancer of the bladder, lung and skin. Consequently, urinary levels of As and Se after each treatment cycle with Pt-based chemotherapeutic drugs could be important for a better understanding of the carcinogenic mechanism of As exposure and about the hypothetic cancer-protective effects of Se. Genetic and epigenetic processes appear to be involved in cancer mechanisms. Epigenetic studies focus on the stress that As provokes in cells without affecting DNA, but directly influences the genome expression. In this complementary mechanism, As participates as an ‘opportunistic carcinogen’ that enhances the genotoxicity and mutagenicity of other environmental stressors, for instance, other trace elements.
During Pt-based drug treatments, patients are exposed to an acute impact of Pt. This subjects cellular homeostasis to deliberate stress by Pt, inducing toxic and, perhaps, hormesic responses. Among cancer patients exposed chronically to arsenic and treats with Pt-drugs based Mg, Zn, Se, As and Pt can participate synergistically in the regulated and unregulated activation of apoptosis, phagocytosis and cellular homeostasis involved in toxicological and hormesis mechanisms.18,20,76,78–80

Conclusions
Overall, despite significant variation in Pt amounts supplied from Pt-based drugs, the amounts of Pt in 24-h urine samples were not significantly different between patients with lung cancer and those with other cancers treated with cisplatin. With respect to the baseline status of patients, the analytical amounts of excreted Mg, Zn and Se were greater than those for As, particularly, for cisplatin chemotherapy. This finding could imply that, with regard to As displacement, Pt favours also the excretion of Mg, Zn and Se. For other types of cancers treated with drugs without Pt, excretion of Mg, Zn and Se was also greater than that of As, suggesting an antagonist Mg, Zn, Se-anticancer drug relationship.

The knowledge obtained in this work and in the related work81 can contribute to understanding the cancer mechanism of As in a multi and inter-element scenario among Mg-Zn-As-Se-Pt for lung cancer as well as other types of cancer. Elements with similar electron arrangements are often antagonists in biological systems,82 which can be rationalised by the Hard/Soft/Acid/Base principle.83 The antagonism and/or synergism among these elements can be intrinsic to the cancerous metalloid-dependent mechanism of the As-Se pair, the exogenic Pt participation in healing, cancer propagation or metastasis and the essentiality of the Mg-Zn pair. Further research including more elements is in progress.

Declarations
Competing Interests: None declared
Funding: None declared
Ethical approval: University of Antofagasta ethics committee approves this study.
Guarantor: DAR
Contributorship: All authors contributed the design, experimental, data analysis and write-up of the present work, and approved the final version.
Acknowledgements: Part of this research was supported by resources generated by the Bioinorganic and Environmental
Analytical Chemistry Laboratory, Chemistry Department, Basic Science Faculty, University of Antofagasta, through the University of Antofagasta Technical Assistance Office. The authors are grateful for having been authorised to access urine samples at the Oncological Center of Antofagasta Regional Hospital.

Provenance: Not commissioned; peer-reviewed by Antonia Maria Palacios.

References
1. Selinus O. Medical geology: an emerging specialty. *Terrae* 2004; 1: 8–15.
2. Selinus O, Alloway JA, Centeno RB, Finkelman RF and Smedley VP. *Essential of medical geology. Impact of the natural environmental on public health*. London: Elsevier, 2005.
3. Madden EF. The role of combined metal interactions in metal carcinogenesis. A review. *Rev Environ Health* 2003; 18: 91–109.
4. Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinmaus C, Selvin S, et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. *J Natl Cancer Inst* 2007; 99: 920–928.
5. Román DA, Pizarro I, Rivera L, Cámaras C, Palacios MA, Gómez MM, et al. An approach to the arsenic status in cardiovascular tissues of patients with coronary heart disease. *Hum Exp Toxicol* 2010; 30: 1150–1164.
6. Fraser B. Cancer cluster in Chile linked to arsenic contamination. *Lancet* 2012; 379: 603.
7. Fernández MI, López JF, Vivaldi B and Coz F. Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure. *J Urol* 2012; 187: 856–861.
8. Correa JA, Ramirez MA, De La Harpe JP, et al. Copper, copper mining effluents and grazing as potential determinants of algal abundance and diversity in Northern Chile. *Env Mon Assess* 2000; 61: 265–281.
9. Ferreccio C and Sancha AM. Arsenic exposure and its impact on health in Chile. *J Health Popul Nutr* 2006; 24: 164–175.
10. Rahman M. International research on arsenic contamination and health. *J Health Popul Nutr* 2006; 24: 123–128.
11. Smith AH, Ercumen A, Juan J and Steinmaus CM. Increased lung cancer risks are similar whether arsenic is ingested or inhaled. *J Expo Sci Environ Epidemiol* 2009; 9: 343–348.
12. Smith A, Marshall G, Yuan Y, Ferreccio C, Liaw J, Von Ehrenstein O, et al. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. *Environ Health Perspect* 2006; 114: 1293–1296.
13. Pizarro AM, Habtemariam A and Sadler PJ. Activation mechanisms for organometallic anticancer complexes. *Top Organomet Chem* 2010; 32: 21–56.
14. Marques MPM. Platinum and palladium polynuclear complexes as anticancer agents. The structural factor. *ISRN Spectrosc* 2013; 2013: 1–29.
15. Liu Zhe and Sadler PJ. Organoiridium complexes: anticancer agents and catalysts. *Acc Chem Res* 2014; 47: 1174–1185.
16. Kelleand L. The resurgence of platinum-based cancer chemotherapy. *Nat Rev* 2007; 7: 573–584.
17. Kalavrouziotis IK and Koukoulakis PH. The environmental impact of the platinum group elements (Pt, Pd, Rh) emitted by the automobile catalyst converters. *Water Air Soil Pollut* 2009; 196: 393–402.
18. Kuo MT, Chen HHW, Song IS, Savaraj N and Ishikawa T. The roles of copper transporters in cisplatin resistance. *Cancer Metastasis Rev* 2007; 26: 71–83.
19. Bharti SK and Singh SK. Recent developments in the field of anticancer metallopharmaceuticals. *Int J Pharm Tech Res* 2009; 1: 1406–1420.
20. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RHJ and Wiemer EAC. Drug transporters of platinum-based anticancer agents and their clinical significance. *Drug Resist Updat* 2011; 14: 22–34.
21. Heffter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M and Elbling L. Resistance against novel anticancer metal compounds: differences and similarities. *Drug Resist Updat* 2008; 11: 1–16.
22. Chen Y, Jungsuwadee P, Vore M, Butterfield DA and St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in non-targeted tissues. *Mol Interventions* 2007; 3: 147–156.
23. Gurney M. How to calculate the dose of chemotherapy. *Br J Cancer* 2002; 86: 1297–1302.
24. Mathijssen RHJ, De Jong FA, Loos WJ, Van Der Bol JM, Verweij J and Sparreboom A. Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: does it make a difference? *Oncologist* 2007; 12: 913–923.
25. Rossman TG and Uddin AN. Selenium prevents spontaneous and arsenite-induced mutagenesis. *Int Congr Ser* 2004; 1275: 173–179.
26. Agusa T, Nomura K, Kunito T, Anaya I and Miyazaki N. Interelement relationships and age-related variation of trace element concentrations in liver of striped dolphins (*Stenella coeruleoalba*) from Japanese coastal waters. *Mar Pollut Bull* 2008; 57: 807–815.
27. Spallholz JE, Boylan LM and Rhaman MM. Environmental hypothesis: is poor dietary selenium intake an underlying factor for arsenicosis and cancer in Bangladesh and West Bengal, India? *Sci Total Environ* 2004; 323: 21–32.
28. Zeng H, Uthus EO and Combs GF Jr. Mechanistic aspects of the interaction between selenium and arsenic. *J Inorg Biochem* 2005; 99: 1269–1212.
29. Pilsner JR, Hall MN, Liu X, Ahsan H, Litvack V, Staykovich V, et al. Associations of plasma selenium intake an underlying factor for arsenicosis and cancer in Bangladesh and West Bengal, India? *Eur J Nutr* 2008; 47: 29–50.
30. Combs GF, Watts JC, Jackson MJ, Johnson LK, Zeng H, Scheett AJ, et al. Determinants of selenium status in healthy adults. *Nutr J* 2011; 10: 75.
32. Reddy YVK, Reddy PS and Shivalingam MR. Cisplatin or carboplatin caused suppression in anti-oxidant enzyme defense system in liver, kidney and testis of male albino rats. J Biomed Sci Res 2010; 2: 23–28.
33. Waseem M and Parvez S. Mitochondrial dysfunction mediated cisplatin induced toxicity: modulatory role of curcumin. Food Chem Toxicol 2013; 53: 334–342.
34. Selenium in Health and Disease III. Nonendemic selenium-responsive conditions, cancer, and coronary vascular disease. Selenium Food Health 2006; 2006: 111–133.
35. Blessing H, Kraus S, Heindl P, Bal W and Hartwig A. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004; 271: 3190–3199.
36. Dodig S and Cepelak I. The facts and controversies about selenium. Acta Pharm 2004; 54: 261–276.
37. Stone RL, Sood AK and Coleman RL. Collateral damage: toxic effects of targeted anti-angiogenic therapies in ovarian cancer. Lancet Oncol 2010; 11: 265–275.
38. Pani G, Galeotti T and Chiarugi P. Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Rev 2010; 29: 351–378.
39. Novotny L, Rauko P, Kombian SB and Edafiogho JO. Selenium as a chemoprotective anti-cancer agent: reality or wishful thinking? Neoplasma 2010; 57: 383–391.
40. Ledesma ML, Jung-Hynes B, Schmit TL, Kumar R, Mukhtar H and Ahmad N. Selenium and Vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol Med 2011; 17: 134–143.
41. Schrauzer GN. Selenium and selenium-antagonistic elements in nutritional cancer prevention. Crit Rev Biotechnol 2009; 1: 7–10.
42. Vahter M, Bjorkman L and Goessler W. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004; 271: 3190–3199.
43. Fletcher JI, Haber M, Henderson J and Norris MD. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004; 271: 3190–3199.
44. Waseem M and Parvez S. Mitochondrial dysfunction mediated cisplatin induced toxicity: modulatory role of curcumin. Food Chem Toxicol 2013; 53: 334–342.
45. Selenium in Health and Disease III. Nonendemic selenium-responsive conditions, cancer, and coronary vascular disease. Selenium Food Health 2006; 2006: 111–133.
46. Blessing H, Kraus S, Heindl P, Bal W and Hartwig A. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004; 271: 3190–3199.
47. Stone RL, Sood AK and Coleman RL. Collateral damage: toxic effects of targeted anti-angiogenic therapies in ovarian cancer. Lancet Oncol 2010; 11: 265–275.
48. Pani G, Galeotti T and Chiarugi P. Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Rev 2010; 29: 351–378.
49. Novotny L, Rauko P, Kombian SB and Edafiogho JO. Selenium as a chemoprotective anti-cancer agent: reality or wishful thinking? Neoplasma 2010; 57: 383–391.
50. Ledesma ML, Jung-Hynes B, Schmit TL, Kumar R, Mukhtar H and Ahmad N. Selenium and Vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol Med 2011; 17: 134–143.
51. Schrauzer GN. Selenium and selenium-antagonistic elements in nutritional cancer prevention. Crit Rev Biotechnol 2009; 1: 7–10.
52. Vahter M, Bjorkman L and Goessler W. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004; 271: 3190–3199.
53. Fletcher JI, Haber M, Henderson J and Norris MD. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004; 271: 3190–3199.
54. Waseem M and Parvez S. Mitochondrial dysfunction mediated cisplatin induced toxicity: modulatory role of curcumin. Food Chem Toxicol 2013; 53: 334–342.
55. Selenium in Health and Disease III. Nonendemic selenium-responsive conditions, cancer, and coronary vascular disease. Selenium Food Health 2006; 2006: 111–133.
56. Blessing H, Kraus S, Heindl P, Bal W and Hartwig A. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004; 271: 3190–3199.
57. Stone RL, Sood AK and Coleman RL. Collateral damage: toxic effects of targeted anti-angiogenic therapies in ovarian cancer. Lancet Oncol 2010; 11: 265–275.
58. Pani G, Galeotti T and Chiarugi P. Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Rev 2010; 29: 351–378.
59. Novotny L, Rauko P, Kombian SB and Edafiogho JO. Selenium as a chemoprotective anti-cancer agent: reality or wishful thinking? Neoplasma 2010; 57: 383–391.
60. Ledesma ML, Jung-Hynes B, Schmit TL, Kumar R, Mukhtar H and Ahmad N. Selenium and Vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol Med 2011; 17: 134–143.
61. Schrauzer GN. Selenium and selenium-antagonistic elements in nutritional cancer prevention. Crit Rev Biotechnol 2009; 1: 7–10.
62. Vahter M, Bjorkman L and Goessler W. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004; 271: 3190–3199.
63. Fletcher JI, Haber M, Henderson J and Norris MD. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004; 271: 3190–3199.
63. Momcilovic B, Prejac J, Brundic S, Morovic S, Skalny AV, Mimica N, et al. An essay on human and elements, multielement profiles, and depression. *Transl Neurosci* 2010; 4: 322–334.

64. Committee on Research Priorities for Earth Science and Public Health. *Hearth materials and health. Research priorities for earth science and public health.* Washington, DC: The National Academies Press, National Research Council and Institute of Medicine of the National Academies, 2007, p.188.

65. Barracough LH, Field C, Wieringa G, Swindell R, Livsey JE and Davidson SE. Estimation of renal function – what is appropriate in cancer patients? *Clin Oncol* 2008; 20: 721–726.

66. Sinkeler SJ, Visser FW, Krikken JA, Stegeman CA, Homan van der Heide JJ and Navis G. Higher body mass index is associated with higher fractional creatinine excretion in healthy subjects. *Nephrol Dial Transplant* 2011; 26: 3181–3188.

67. Planet G. Comparison of creatinine clearance estimates with routine measured clearance. *Clin Biochem* 2007; 40: 124–127.

68. Barr DB, Wilder LC, Caudill SP, González AJ, Needham LL and Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. *Environ Health Perspect* 2005; 113: 192–200.

69. Rivera L, Ávila J, Morales T, Cortés P, Román D and Vergara L. Distribución de elementos traza y metales pesados en tejidos placentarios de recién nacidos normales (RNN). Enfoque analítico multimetalico. Versión en disco compacto. VIII Encuentro de Química Analítica Ambiental, Sociedad Chilena de Química. Iquique, Chile: Universidad Arturo Prat, 2006.

70. Pizarro I, Román D, Ávila J, Morales T, Cortés P and Solar C. Status analítico bioinorgánico de elementos traza en tejidos cardiovasculares de pacientes sometidos a cirugía cardíaca. Versión en disco compacto. VIII Encuentro de Química Analítica Ambiental, Sociedad Chilena de Química. Iquique, Chile: Universidad Arturo Prat, 2006.

71. Forina M, Armanino C and Raggio V. Clustering with dendrograms on interpretation variables. *Anal Chim Acta* 2002; 454: 13–19.

72. Pletnev I and Zernov V. Classification of metal ions according to their complexing properties: a data-driven approach. *Anal Chim Acta* 2002; 455: 131–142.

73. Thompson LA, Lawson AP, Sutphin SD, Steinke D and Adams VR. Description of current practices of empiric chemotherapy dose adjustment in obese adult patients. *J Oncol Pract* 2010; 6: 141–145.

74. Yuan Y, Marshall G, Ferreccio C, Steinmaus C, Selvin S, Liaw J, et al. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed Region II of Chile from 1950 to 2000. *Am J Epidemiol* 2007; 166: 1381–1391.

75. Andrew AS, Burgess JL, Meza MM, Demidenko E, Waugh MG, Hamilton JW, et al. Arsenic exposure is associated with decreased DNA repair in vitro and individuals exposed to drinking water arsenic. *Environ Health Perspect* 2006; 114: 1193–1198.

76. Ren X, Aleshin M, Jo WJ, Dills R, Kalman DA and Vulpe CD. Involvement of N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) in arsenic biomethylation and its role in arsenic-induced toxicity. *Environ Health Perspect* 2011; 119: 771–777.

77. Ren X, McHale CM, Skibola CF, Smith AH, Smith MT and Zhang L. An emerging role for epigenetic deregulation in arsenic toxicity and carcinogenesis. *Environ Health Perspect* 2011; 119: 11–19.

78. Bozhkov A, Padalko V, Dlubovskaya V and Menziano N. Resistance to heavy metal toxicity in organisms under chronic exposure. *Indian J Exp Biol* 2010; 48: 679–696.

79. Hou L, Wang D and Baccarelli A. Environmental chemicals and micro RNAs. *Mutat Res* 2011; 714: 105–112.

80. Hanekamp JC. Micronutrients, hormesis and the aptitude for the maturation of regulation. *Am J Pharm Toxicol* 2008; 3: 144–151.

81. Román DA, Pizarro I, Rivera L, Torres C, Ávila J, Cortés P, et al. Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs. *BMC Res Notes* 2012; 5: 207, 1–12.

82. Marmiroli N and Maestri E. Health implications of trace elements in the environment and the food chain. In: Prasad MNV (ed.) *Trace elements as contaminants and nutrients: Consequences in ecosystems and human health*. Hoboken: Wiley, 2008, pp.23–53.

83. Pearson RG (ed). *Chemical hardness. Applications from molecules to solids*. Hoboken: Wiley, 1997.